Regeneron/Sanofi wins U.S. approval for expanded use of skin drug

The U.S. Food and Drug Administration on Monday approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged 12 and older, a boost for both the companies in the world's largest market for drugs.